Short-term safety assessment in the use of intravenous zoledronic acid in children

Wolfgang Högler; Fabian Yap; David Little; Geoffrey Ambler; Mary McQuade; Christopher T Cowell

doi:10.1016/j.jpeds.2004.06.066

Short-term safety assessment in the use of intravenous zoledronic acid in children

J Pediatr. 2004 Nov;145(5):701-4. doi: 10.1016/j.jpeds.2004.06.066.

Authors

Wolfgang Högler¹, Fabian Yap, David Little, Geoffrey Ambler, Mary McQuade, Christopher T Cowell

Affiliation

¹ Institute of Endocrinology and Diabetes, Department of Orthopedics, The Children's Hospital of Westmead, Sydney, Australia.

PMID: 15520785
DOI: 10.1016/j.jpeds.2004.06.066

Abstract

The clinical side effects of the potent new bisphosphonate zoledronic acid in children are unknown. In this study of 34 children with various bone disorders, the frequency of postinfusion flu-like illness, hypocalcemia, and hypophosphatemia was 85%, 74%, and 82%, respectively. No renal side effects were detected after up to 3 consecutive infusions.

MeSH terms

Adolescent
Bone Resorption / metabolism*
Bone Resorption / prevention & control
Calcium / blood
Child
Child, Preschool
Creatinine / blood
Diphosphonates / administration & dosage
Diphosphonates / adverse effects*
Female
Fever / chemically induced
Follow-Up Studies
Humans
Imidazoles / administration & dosage
Imidazoles / adverse effects*
Infusions, Intravenous
Male
Nausea / chemically induced
Pain / chemically induced
Phosphorus / blood
Retrospective Studies
Time Factors
Urea / blood
Vomiting / chemically induced
Zoledronic Acid

Substances

Diphosphonates
Imidazoles
Phosphorus
Zoledronic Acid
Urea
Creatinine
Calcium